Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.1 USD | +2.41% | +2.59% | +2.14% |
May. 31 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
May. 31 | European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected | MT |
Financials (USD)
Sales 2024 * | 49.08B | Sales 2025 * | 51.18B | Capitalization | 210B |
---|---|---|---|---|---|
Net income 2024 * | 10.48B | Net income 2025 * | 11.74B | EV / Sales 2024 * | 4.53 x |
Net Debt 2024 * | 12.07B | Net Debt 2025 * | 10.61B | EV / Sales 2025 * | 4.32 x |
P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
17.3
x | Employees | 76,057 |
Yield 2024 * |
3.51% | Yield 2025 * |
3.64% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | +2.41% | ||
1 week | +2.59% | ||
1 month | +5.77% | ||
3 months | +1.05% | ||
6 months | +5.10% | ||
Current year | +2.14% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.01% | 13 M€ | -.--% | ||
1.52% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 103.1 | +2.41% | 1,981,421 |
24-05-30 | 100.7 | +1.35% | 1,258,059 |
24-05-29 | 99.36 | -0.32% | 1,108,549 |
24-05-28 | 99.68 | -0.85% | 1,033,525 |
24-05-24 | 100.5 | -0.57% | 1,177,608 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- NOVN Stock
- NVS Stock